Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
editorial
. 1997 Oct;110(1):122–126. doi: 10.1046/j.1365-2249.1997.4591358.x

Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab′)2-mediated anti-complement activity

CH LATREMOUILLE *, D GENEVAZ *, M C HU *, O SCHUSSLER *, N GOUSSEF *, C MANDET *, P BRUNEVAL *, N HAEFFNER-CAVAILLON *, A CARPENTIER *, D GLOTZ *
PMCID: PMC1904796  PMID: 9353158

Abstract

Xenotransplantation between discordant species leads to a hyperacute rejection mediated by natural antibodies, both of the IgG and IgM isotypes, activation of complement and endothelial cell activation. The combination of these mechanisms leads to a transplant survival of minutes to a few hours. Polyclonal human immunoglobulins for intravenous use (IVIg) from normal donors have proved effective in a number of antibody-mediated disorders, as well as in inflammatory disorders. We demonstrate that administration of IVIg in a guinea pig to rat model of cardiac xenografting can effectively delay hyperacute rejection. This effect is mediated by the F(ab′)2 fragments of IVIg, and is correlated to an anti-complementary activity.

Keywords: xenotransplantation, complement, IVIg

Full Text

The Full Text of this article is available as a PDF (403.0 KB).


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES